Prestige BioPharma Limited (950210.KS)

KRW 15050.0

(-4.57%)

Total Debt Summary of Prestige BioPharma Limited

  • Prestige BioPharma Limited's latest annual total debt in 2023 was 89.66 Billion KRW , up 6.27% from previous year.
  • Prestige BioPharma Limited's latest quarterly total debt in 2023 Q3 was 87.98 Billion KRW , up 1.92% from previous quarter.
  • Prestige BioPharma Limited reported annual total debt of 84.37 Billion KRW in 2022, up 1885.6% from previous year.
  • Prestige BioPharma Limited reported annual total debt of 4.24 Billion KRW in 2021, down -45.32% from previous year.
  • Prestige BioPharma Limited reported quarterly total debt of 86.05 Billion KRW for 2023 Q1, up 2.0% from previous quarter.
  • Prestige BioPharma Limited reported quarterly total debt of 87.98 Billion KRW for 2023 Q3, up 1.92% from previous quarter.

Annual Total Debt Chart of Prestige BioPharma Limited (2023 - 2017)

Historical Annual Total Debt of Prestige BioPharma Limited (2023 - 2017)

Year Total Debt Total Debt Growth
2023 89.66 Billion KRW 6.27%
2022 84.37 Billion KRW 1885.6%
2021 4.24 Billion KRW -45.32%
2020 7.77 Billion KRW 169.97%
2019 2.87 Billion KRW -84.46%
2018 18.52 Billion KRW 172.62%
2017 6.79 Billion KRW 0.0%

Peer Total Debt Comparison of Prestige BioPharma Limited

Name Total Debt Total Debt Difference
ORIENT BIO Inc. 3.03 Billion KRW -2849.857%
Green Cross Holdings Corporation 1280.16 Billion KRW 92.996%
Green Cross Holdings Corporation 724.02 Billion KRW 87.615%
Pharmicell Co., Ltd. 3.02 Billion KRW -2861.523%
Green Cross Corporation 724.02 Billion KRW 87.615%
GeneOne Life Science, Inc. 17.15 Billion KRW -422.548%
Celltrion, Inc. 1890.42 Billion KRW 95.257%
Samsung Biologics Co.,Ltd. 1909.33 Billion KRW 95.304%
SK bioscience Co.,Ltd. 20.57 Billion KRW -335.837%
SK Biopharmaceuticals Co., Ltd. 178.05 Billion KRW 49.639%